华熙生物控股股东增持计划进展要点解读 增持计划基本情况 •增持主体：控股股东华熙昕宇投资有限公司 •增持期间：2025年8月8日至2026年2月7日（6个月） •增 持规模：金额2-3亿元，股份比例不超过总股本1% •增持价格：不超过70元/股 首次增持执行情况 关键信息 • 控股股东将继续按计划用自有或自筹资金执行后续增持 • 本次增持不会导致控股股东及实控人发生变 化 • 公司将按规定及时披露增持进展 •增持时间：2025年8月27-28日 •增持数量：153.36万股，占总股本0.32% •增持金额：8,868.30万元 •增持 方式：上交所集中竞价交易 股东持股结构 •增持前持股：华熙昕宇持股2.835亿股，占比58.86% •一致行动人：包括实控人赵燕女士等，合计持股 59.17% ...

证券代码：688363 证券简称：华熙生物 公告编号：2025-032 增持计划无法实施风险：本次增持计划可能存在因资本市场情况发生变 化或目前尚无法预判的其他风险因素导致增持计划的实施无法达到预期的风险。 华熙生物科技股份有限公司 关于控股股东首次增持公司股份暨增持计划进展的 公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 已披露增持计划情况：华熙生物科技股份有限公司（以下简称"华熙生 物""公司"）的控股股东华熙昕宇投资有限公司（以下简称"华熙昕宇"）基于 对公司未来发展的信心和长期投资价值认可，计划自 2025 年 8 月 8 日起的 6 个 月内，使用自有资金或自筹资金，通过上海证券交易所系统允许的方式（包括 但不限于集中竞价、大宗交易等）增持公司股份，增持金额不低于人民币 2 亿 元（含），不超过人民币 3 亿元（含），增持股份比例不超过公司总股本 1%，增 持股票价格不超过 70 元/股。具体内容详见公司于 2025 年 8 月 8 日在上海证券 交易所网站（www.sse.com. ...

Core Viewpoint - Since 2023, Huaxi Bio has faced significant challenges but showed signs of recovery in the second quarter of 2025, indicating a potential return to growth driven by internal reforms initiated by Chairman Zhao Yan [3][4][20]. Financial Performance - In the first half of 2025, Huaxi Bio reported total revenue of 2.261 billion, a year-on-year decrease of 19.57%, and a net profit attributable to shareholders of 221 million, down 35.38% [7][9]. - In the second quarter of 2025, the company achieved revenue of 1.183 billion, a decrease of 18.44% year-on-year, but net profit increased by 20.89% to 119 million, marking a significant turnaround [8][10]. Operational Changes - Zhao Yan's return to frontline operations in March 2025 marked a pivotal moment for the company, leading to a series of organizational reforms aimed at enhancing efficiency and reducing bureaucratic inertia [13][15][20]. - The company shifted its marketing strategy from price promotions to a more scientific and content-driven approach, significantly reducing sales expenses by 31.44% [10][19]. Research and Development - R&D expenses increased by 15.25% year-on-year, reaching 231 million, which accounted for 10.22% of total revenue, reflecting a strategic focus on core research areas [29][30]. - The company optimized over 30% of its R&D projects, leading to the launch of six new raw materials and the recognition of its technology on an international level [30][31]. Market Position and Strategy - Huaxi Bio's core business segments, including raw materials and medical terminals, remain strong, with a combined revenue share of 57.5% [24]. - The company is focusing on deep breakthroughs in R&D, particularly in extracellular matrix and cellular communication, to address aging and tissue regeneration [28][32]. Future Outlook - The company is well-positioned to benefit from the recovery of the cosmetics market in 2025, particularly in the functional skincare segment, aligning its reforms with market trends [33]. - Huaxi Bio's strategic shift towards a more integrated approach in manufacturing and branding is expected to enhance its long-term growth potential [33].

Group 1 - The medical beauty sector increased by 0.6% on August 28, with Huaxi Biological leading the gains [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] - The closing prices and performance of key stocks in the medical beauty sector include: - Huaxi Biological: 57.78, up 1.60%, with a trading volume of 82,100 shares and a turnover of 471 million yuan - Aimeike: 190.36, up 0.17%, with a trading volume of 49,700 shares and a turnover of 940.1 million yuan - Jinbo Biological: 299.27, down 1.81%, with a trading volume of 9,644 shares and a turnover of 289 million yuan - *ST Meigu: 3.21, down 3.60%, with a trading volume of 195,800 shares and a turnover of 62.64 million yuan [1] Group 2 - The medical beauty sector experienced a net outflow of 122 million yuan from main funds, while retail funds saw a net inflow of 66.68 million yuan [1] - The fund flow for key stocks shows: - *ST Meigu: net outflow of 5.87 million yuan, down 9.37% - Huaxi Biological: net outflow of 27.85 million yuan, down 5.92% - Aimeike: net outflow of 88.21 million yuan, down 9.39% [2]

Group 1 - The biopharmaceutical ETF (159859) experienced a slight decline of 0.7% as of the report date, with a trading volume exceeding 600 million yuan, making it the top performer among its peers [1] - The ETF has seen a net inflow of over 39 million yuan in the past two days, with a net subscription of 38 million units on August 27, bringing its total circulation to 7.141 billion units [1] - The ETF closely tracks the National Index of Biopharmaceuticals (399441.SZ), covering various sectors including innovative drugs, CXO, vaccines, and blood products, and is noted for its size and liquidity [1] Group 2 - The Tianhong innovative drug ETF (517380) is the largest in the market, covering both A-shares and Hong Kong stocks, and is the only ETF tracking the Hang Seng-Hushen-Hong Kong Innovative Drug Selected 50 Index [2] - The upcoming 2025 World Lung Cancer Conference (WCLC) in Barcelona is expected to showcase over 40 Chinese research projects, highlighting the importance of academic conferences as catalysts for the innovative drug sector [2][3] - The overall outlook for the innovative drug sector is positive, with expectations of improved fundamentals and potential profitability by 2026, alongside a hot market for overseas licensing and business development transactions [3]

Investment Rating - The report maintains a "Buy" rating for the company [1]. Core Views - The company has shown significant improvement in profits in Q2 2025, with a notable recovery in net profit compared to Q1 2025 [1][10]. - The chairman's active involvement in management is expected to drive positive changes in the company's performance in the second half of the year [10]. - The company is undergoing a transformation towards an "efficiency-oriented" approach, which has led to a significant reduction in sales expense ratios [9][10]. Financial Performance Summary - For the first half of 2025, the company reported revenues and net profits of 2.26 billion and 220 million yuan, respectively, reflecting year-on-year declines of 19.6% and 35.4% [4]. - Q2 2025 saw revenues and net profits of 1.18 billion and 120 million yuan, with a year-on-year decline of 18.4% in revenue but a 20.9% increase in net profit [4]. - The company's gross margin for the first half of 2025 was 71.0%, down 3.5 percentage points year-on-year [8]. Business Segment Performance - The raw materials segment showed resilience, with revenue of 630 million yuan, a slight decline of 0.6% year-on-year, while the medical terminal products segment generated 670 million yuan, down 9.4% [5]. - The skin science innovation transformation business experienced a significant decline of 34.0% in revenue, totaling 910 million yuan, while the nutrition science innovation transformation business grew by 32.4% to 40 million yuan [5]. - The company launched several new medical aesthetic products in 2025, contributing to a diversified product matrix [6]. Market Outlook - The company is expected to return to a positive growth trajectory, with revenue forecasts adjusted to 4.825 billion, 5.631 billion, and 6.735 billion yuan for 2025, 2026, and 2027, respectively [11]. - The report anticipates that the company's earnings per share (EPS) will be 0.98, 1.23, and 1.66 yuan for 2025, 2026, and 2027, respectively [11]. - The chairman's plan to increase shareholding by 200 to 300 million yuan within six months reflects confidence in the company's future development [11].

Group 1 - The beauty and personal care sector experienced a significant surge, with Lafang Home Technology reaching its daily limit up [1] - Other companies such as Nobon Co., Jeya Co., Shuiyang Co., Beitaini, Jiahen Home Technology, and Huaxi Biological also saw increases in their stock prices [1]

Core Viewpoint - Huaxi Biological, a leading hyaluronic acid company, continues to face pressure on its performance, with significant declines in revenue and net profit in the first half of 2025 [1] Financial Performance - In the first half of 2025, Huaxi Biological reported revenue of 2.261 billion yuan and a net profit attributable to shareholders of 221 million yuan, representing year-on-year declines of 19.57% and 35.38% respectively [1] - In the second quarter, the company's revenue was 1.183 billion yuan, down nearly 20% year-on-year [2] - The skincare innovation business, a key revenue driver, generated 912 million yuan, experiencing a decline of over 30% year-on-year [2] Industry Comparison - The company's performance significantly lags behind the industry, with China's cosmetic retail sales reaching 229.1 billion yuan in the first half of 2025, a year-on-year growth of 2.9% [3] - Competitors such as Proya and Shuiyang reported nearly 10% year-on-year revenue growth during the same period [3] Cost Management - Huaxi Biological has significantly reduced its sales expenses, which amounted to 808 million yuan in the first half of 2025, down 31.44% year-on-year, accounting for 35.74% of revenue, a decrease of over 6 percentage points [3] - The company has ceased price promotion campaigns on various platforms, aiming to restructure its brand's technical foundation for better customer acquisition models [3] Business Strategy - The company is adopting a "price-for-volume" strategy to boost sales of its medical beauty products, with medical product revenue at 467 million yuan, down 1.8% year-on-year, while sales of three types of medical devices increased by 20% [3] - Huaxi Biological plans to optimize its product structure and channel layout to adapt to market changes [4] Brand Development - The medical beauty brands "Run Bai Yan" and "Run Zhi" have been launched on the Meituan medical beauty platform to enhance user reach [6] - The chairman of Huaxi Biological, Zhao Yan, has returned to frontline operations to boost performance, although the effectiveness of these reforms may take more time to manifest [6]

Group 1: ETF Performance - The Tianhong Food and Beverage ETF (159736) recorded a transaction volume of 7.8005 million yuan, with New Dairy Industry (002946) leading gains at 5.26% [3] - The Biopharmaceutical ETF (159859) experienced a trading volume of 37.8004 million yuan, with Huaxi Biological (688363) leading at 1.49% [3] - As of August 27, the Tianhong Food and Beverage ETF reached a new high with 7.110 billion shares outstanding [3] - The Tianhong Food and Beverage ETF saw a net inflow of 146 million yuan over the past week [3] - The Biopharmaceutical ETF had an average daily transaction of 155 million yuan over the past week, ranking first among comparable funds [3] - The Biopharmaceutical ETF's scale increased by 72.4188 million yuan over the past two weeks, with a weekly share increase of 5.400 million shares [3] Group 2: ETF Composition and Market Context - The Tianhong Food and Beverage ETF closely tracks the CSI Food and Beverage Index, which includes stocks from the beverage, packaged food, and meat industries, featuring major stocks like Kweichow Moutai and Yili [4] - The Biopharmaceutical ETF tracks the National Biopharmaceutical Index, covering various sectors including innovative drugs and vaccines, and is noted for its liquidity and scale [4] - The National Development and Reform Commission announced the allocation of 690 billion yuan for consumer goods replacement programs, with plans for a fourth batch of funding in October [4] Group 3: Industry Insights - The Pacific Securities report indicates that the liquor sector is at a turning point, with the SW liquor index rising by 0.83%, reflecting a focus on operational improvements and stock price recovery [5] - The report highlights that the market has recognized the short-term performance pressures on liquor companies, with concerns mainly around sales feedback and price transmission [5] - In the consumer goods sector, the report suggests monitoring companies with better-than-expected performance and operational improvements, while maintaining a long-term outlook on new channel transformations and emerging product categories [5]

Core Viewpoint - Huaxi Biological is experiencing a painful period of performance decline, with significant drops in both revenue and net profit in the first half of 2025 compared to the previous year [1][2] Financial Performance - In the first half of 2025, Huaxi Biological reported revenue of 2.261 billion yuan, a year-on-year decrease of 19.57% [1] - The net profit attributable to shareholders was 221 million yuan, down 35.38% year-on-year [1] - In Q2 2025, the company achieved revenue of 1.183 billion yuan, a decline of 18.44% year-on-year, while net profit increased by 20.89% to 119 million yuan [1] Business Segment Analysis - The decline in performance is attributed to a significant drop in the skin science innovation transformation business, which saw a 31.62% decrease in revenue in 2024 and continued to decline in the first half of 2025 [1] - Other business segments, including raw materials and medical terminal businesses, also experienced varying degrees of decline, with raw materials revenue at 626 million yuan, a slight decrease of 0.5% [1][2] Reform and Management Changes - The year 2024 was defined as the "year of reform" for Huaxi Biological, with multiple initiatives launched to reshape business processes and organizational structures [1] - In Q2 2025, the chairman and general manager, Zhao Yan, took direct control of core business segments to accelerate strategic implementation [1][2] - The company reported a turnover in its personnel structure, with 11 executives leaving and an increase of 35 R&D staff, although average salaries decreased year-on-year [2] R&D Investment - In the first half of 2025, Huaxi Biological invested 231 million yuan in R&D, a year-on-year increase of 15.25%, focusing on high-barrier products and bioactive materials [2] - The number of R&D projects decreased by 88 compared to 2024, indicating a shift in focus towards more strategic areas [2] Market Comparison - In contrast to Huaxi Biological, competitor Jinbo Biological reported revenue of 859 million yuan in the first half of 2025, a year-on-year increase of 42.43%, highlighting the competitive pressures in the functional skincare market [2]